Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Personalized Tumor Neoantigen-loaded DC Vaccine Combined with PD-1 Inhibitor and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

NCT06751849 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Nanchang University as lead sponsor.

NCT NCT06751849
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06751849 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Personalized Tumor Neoantigen-loaded DC Vaccine Combined with PD-1 Inhibitor and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
Lead sponsor
The First Affiliated Hospital of Nanchang University
Phase
Phase 2
Overall status
Recruiting
Start date
March 11, 2024
Completion date
June 10, 2026
Enrollment
10 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced nsclc